Login to Your Account



Karyopharm Prices Upsized IPO

Intermune Pads Cash with $84.5M to Widen ‘PANORAMA’ for Esbriet

By Jennifer Boggs
Managing Editor

Wednesday, November 6, 2013
On the heels of better-than-expected third quarter sales for idiopathic pulmonary fibrosis drug Esbriet (pirfenidone) in Europe, Intermune Inc. priced a public offering to raise $84.5 million to help fund additional studies of Esbriet, including the pivotal trial needed for U.S. approval of the drug and studies to expand its use in IPF and other indications.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription